Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report sent to investors on Monday. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

Shares of NASDAQ:EVOK opened at $4.71 on Monday. The company has a market capitalization of $7.00 million, a P/E ratio of -0.43 and a beta of 0.16. Evoke Pharma has a 1-year low of $3.54 and a 1-year high of $12.32. The firm’s 50 day simple moving average is $4.73 and its two-hundred day simple moving average is $4.81.

Institutional Investors Weigh In On Evoke Pharma

An institutional investor recently raised its position in Evoke Pharma stock. Nantahala Capital Management LLC boosted its stake in Evoke Pharma, Inc. (NASDAQ:EVOK) by 163.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 148,194 shares of the specialty pharmaceutical company’s stock after purchasing an additional 91,945 shares during the quarter. Nantahala Capital Management LLC owned about 9.95% of Evoke Pharma worth $655,000 as of its most recent SEC filing.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.